Journal article

Subcortical shape alterations in major depressive disorder: Findings from the ENIGMA major depressive disorder working group

Tiffany C Ho, Boris Gutman, Elena Pozzi, Hans J Grabe, Norbert Hosten, Katharina Wittfeld, Henry Voelzke, Bernhard Baune, Udo Dannlowski, Katharina Foerster, Dominik Grotegerd, Ronny Redlich, Andreas Jansen, Tilo Kircher, Axel Krug, Susanne Meinert, Igor Nenadic, Nils Opel, Richard Dinga, Dick J Veltman Show all

HUMAN BRAIN MAPPING | WILEY | Published : 2020

Abstract

Alterations in regional subcortical brain volumes have been investigated as part of the efforts of an international consortium, ENIGMA, to identify reliable neural correlates of major depressive disorder (MDD). Given that subcortical structures are comprised of distinct subfields, we sought to build significantly from prior work by precisely mapping localized MDD-related differences in subcortical regions using shape analysis. In this meta-analysis of subcortical shape from the ENIGMA-MDD working group, we compared 1,781 patients with MDD and 2,953 healthy controls (CTL) on individual measures of shape metrics (thickness and surface area) on the surface of seven bilateral subcortical structu..

View full abstract

Grants

Awarded by National Health and Medical Research Council


Awarded by National Institute of Aging


Awarded by National Institute of Biomedical Imaging and Bioengineering


Awarded by National Institute of Mental Health


Awarded by Gratama Foundation


Awarded by Interdisciplinary Center for Clinical Research (IZKF) of the Medical Faculty of Munster


Awarded by German Research Foundation


Funding Acknowledgements

National Health and Medical Research Council, Grant/Award Number: 1140764; National Institute of Aging, Grant/Award Numbers: R01AG059874, R56AG058854, T32AG058507; National Institute of Biomedical Imaging and Bioengineering, Grant/Award Numbers: P41EB015922, U54EB020403; National Institute of Mental Health, Grant/Award Numbers: K01MH117442, R01MH117601, R01MH111671, R01MH116147, T32MH073526, R37MH101495; Biogen, Inc.; Roche Pharmaceuticals and Servier Pharmaceuticals; Fresenius Medical Care and Janssen Cilag; Max Planck Institute of Psychiatry, Munich; European Social Fund (ESF); EU Joint Programme Neurodegenerative Disorders (JPND); Fresenius Medical Care; DAMP Foundation; German Ministry of Education and Research (BMBF); Lundbeck; Gratama Foundation, Grant/Award Number: 2012/35; Interdisciplinary Center for Clinical Research (IZKF) of the Medical Faculty of Munster, Grant/Award Number: Dan3/012/17; German Research Foundation, Grant/Award Numbers: SA 1358/2-1, DFG-SFB779/TPA06, SCHR443/11-1, SCHN 1205/3-1, WA 1539/4-1, FOR2107 JA 1890/7-2, FOR2107 NE 2254/1-2, FOR2107 KI 588/14-2, FOR2107 KR 3822/7-2, SFB-TRR58, DA1151/5-2, FOR2107 DA1151/5-1; Federal State of Mecklenburg-West Pomerania; Siemens Healthineers; German Federal State of Mecklenburg-West Pomerania